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Dear Editors,
We very much appreciate the interest Reifsnider et al. [1] have
taken in our perspective on the single technology appraisal
(STA) of abiraterone acetate (tradename Zytiga) plus pred-
nisolone (AAP) acetate for the treatment of chemotherapy-
naı¨ve metastatic castration-resistant prostate cancer (mCRPC)
prepared for the UK National Institute for Health and Care
Excellence (NICE) [2, 3]. Here, we respond to the aspects
highlighted by Reifsnider et al. [1] and correct factual inaccu-
racies in their reasoning. The main issues are printed in italics
[1]. These points relate to (1) the statistical significance of the
COU-AA-302 survival results and (2) the justification of the
discrete-event simulation (DES) approach utilised by the
company. Reifsnider et al. [1] also highlight aspects that are
unrelated to thesemain points, andwe discuss these separately.
1 Statistical Significance of the COU-AA-302
Survival Results
1. The ERG [evidence review group] alleged that ‘‘it is
unlikely that the trial will ever show a significant
survival benefit’’; however, the final COU-AA-302
overall survival (OS) results were statistically signifi-
cant regardless of crossover [1].
We stated that it was unlikely that the trial would ever
show a significant survival benefit based on the original
unadjusted analysis [2, 3]. The results reported by Ryan
et al. [4] are adjusted for cross-over. These results were
published in January 2015, 10 months after publication of
the final Evidence Review Group (ERG) report in March
2014. In addition, the NICE appraisal committee (AC)
criticized the conduct of the trial by stating,
‘‘The committee was aware that the company
unblinded COU-AA-302 early between the second
and third interim analyses for overall survival and
that, at both of these interim analyses, the results for
overall survival did not show a statistically significant
difference between the treatment arms according to
the pre-specified statistical significance levels.’’ [5]
‘‘The committee discussed the potential effects of
stopping the trial early on the size of the estimates of
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overall survival. The committee noted a systematic
review published in 2010 (Bassler et al.) [6] describing
the bias in trials that stop early for benefit. Specifically,
compared with trials that run to completion, trials that
stop early for benefit overestimate themagnitude of the
treatment effect (that is, have pooled hazard ratios
around 30% lower than trials that run to completion).
The company expressed the belief during consultation
that this bias did not apply to oncology trials, because
the review by Bassler et al. [6] included a minority of
haematology/oncology trials, and because other stud-
ies indicate only a marginal bias towards overestima-
tion in oncology trials that stopped early. However, the
committee concluded that this bias was unrelated to
disease area.’’ [5]
2 Justification of the Discrete-Event Simulation
Approach Utilised
The following points highlighted by Reifsnider et al. [1]
consider the justification of the DES approach utilised:
2. The model was designed to simulate the mCRPC patient
pathway whilst capturing outcomes from COU-AA-302 [1].
3. A DES model utilizing a series of prediction equations
to estimate time-to-event more directly incorporated
trial data, captured patient and treatment interdepen-
dencies, and improved modelling efficiency [1].
4. Whilst the ERG heavily criticized the DES approach,
the NICE Appraisal Committee ultimately accepted the
approach and recommended AAP within its marketing
authorization [1].
We would like to point out here that we did not criticize
the DES approach itself but rather the implementation of
the DES approach, as we do not believe that this was:
‘‘the most transparent approach possible to address
the decision problem defined in the scope. Trans-
parency is a key aspect of modelling and in this
specific case a more transparent model would be
more convenient for an external reviewer to assess
face validity and internal validity of the model.’’ [2]
As mentioned in our original publication, the AC
seemed to agree with us:
‘‘The committee noted that, for two equations, the
company had not followed its own statistical plan
when choosing covariates, and the committee agreed
that this could introduce bias to the model.’’ [2, 7]
‘‘The committee concluded that the company’s model
was complex and lacked transparency, which made it
difficult for the ERG to validate and critique, and for
the AC to determine the plausibility of the model
outcomes.’’ [2, 7]
This indicates that, although the AC based their decision
on the DES model utilised by the company, this does not
imply that the AC also supported the DES approach as
implemented by the company. In this specific case, an
individual patient-level state transition (i.e. Markov) model
might have been easier to implement in a transparent
fashion (as highlighted in the original ERG report [3]).
3 Aspects that are Unrelated to the Main Points
Reifsnider et al. [1] considered it appropriate to use the
complete case analysis instead of the intention-to-treat
(ITT) population (excluding 187 patients [17%] with
incomplete baseline information). As stated previously [3],
we believe that this approach would introduce bias in
favour of AAP for time to treatment discontinuation (TTD)
and hence OS (as OS is dependent on TTD in the DES
model). This is illustrated in Figure 3 in the company’s
response to NICE’s request for additional information [8]
and the company’s response to clarification letter question
B4a [9]. As stated previously, we would ideally have
preferred an approach that used the ITT population while
imputing any missing data [3].
Finally, Reifsnider et al. [1] stated that the ERG pre-
ferred a Weibull distribution (instead of the Log-logistic
distribution) to estimate TTD for the initial treatment. This
is factually incorrect; we did not replace the Log-logistic
distribution with the Weibull distribution in our base case
(this was only explored in scenario analyses) [3].
Compliance with Ethical Standards
Funding This project was funded by the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA) Programme.
See the HTA programme website for further project information
(http://www.hta.ac.uk). The views and opinions expressed herein are
those of the authors and do not necessarily reflect those of NICE or
the Department of Health.
Conflicts of interest Bram Ramaekers, Rob Riemsma, Florian
Tomini, Thea van Asselt, Sohan Deshpande, Steven Duffy, Nigel
Armstrong, Johan Severens, Jos Kleijnen and Manuela A. Joore have
no conflicts of interest.
References
1. Reifsnider O, Hall F, Sorensen S, Proskorovsky I, Girod I, Lee J.
Comment on ‘‘Abiraterone acetate for the treatment of chemother-
apy-naı¨ve metastatic castration-resistant prostate cancer: an Evi-
dence Review Group perspective of an NICE Single Technology
B. L. T. Ramaekers et al.
Appraisal’’. Letter to the Editor. Pharmacoeconomics. 2017.
doi:10.1007/s40273-017-0502-8.
2. Ramaekers BL, Riemsma R, Tomini F, van Asselt T, Deshpande S,
Duffy S, et al. Abiraterone acetate for the treatment of chemother-
apy-naı¨ve metastatic castration-resistant prostate cancer: an Evi-
dence Review Group perspective of an NICE Single Technology
Appraisal. Pharmacoeconomics. 2017;35(2):191–202. doi:10.
1007/s40273-016-0445-5.
3. Riemsma R, Ramaekers BLT, Tomini F, Wolff R, van Asselt ADI,
JooreMA, et al. Abiraterone for the treatment of chemotherapy naı¨ve
metastatic castration-resistant prostate cancer: a Single Technology
Appraisal. York: Kleijnen Systematic Reviews Ltd.; 2014. https://
www.nice.org.uk/guidance/ta387/documents/prostate-cancer-
metastatic-hormone-relapsed-not-treated-with-chemotherapy-
abiraterone-acetate-with-prednisolone-id503-evaluation-report.
Accessed 21 March 2016.
4. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN,
et al. Abiraterone acetate plus prednisone versus placebo plus
prednisone in chemotherapy-naive men with metastatic castration-
resistant prostate cancer (COU-AA-302): final overall survival
analysis of a randomised, double-blind, placebo-controlled phase 3
study. Lancet Oncol. 2015;16(2):152–60. doi:10.1016/S1470-
2045(14)71205-7.
5. National Institute for Health and Care Excellence (NICE).
Abiraterone for treating metastatic hormone-relapsed prostate
cancer not previously treated with chemotherapy. NICE final
appraisal determination. London: NICE; 2014. https://www.nice.
org.uk/guidance/indevelopment/ta387/documents. Accessed 21
March 2016.
6. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q,
et al. Stopping randomized trials early for benefit and estimation of
treatment effects: systematic review and meta-regression analysis.
JAMA. 2010;303(12):1180–7. doi:10.1001/jama.2010.310.
7. National Institute for Health and Care Excellence (NICE).
Abiraterone for treating metastatic hormone-relapsed prostate
cancer not previously treated with chemotherapy. NICE final
appraisal determination 2. London: NICE; 2016. https://www.nice.
org.uk/guidance/indevelopment/ta387/documents. Accessed 21
March 2016.
8. Janssen. Abiraterone acetate for the treatment of metastatic
hormone relapsed prostate cancer not previously treated with
chemotherapy [ID503]. Response to NICE request for additional
information on 22 October 2015: Janssen; 2015. https://www.nice.
org.uk/guidance/GID-TAG434/documents/appraisal-consultation-
document-2. Accessed 21 March 2016.
9. National Institute for Health and Care Excellence (NICE).
Abiraterone acetate for the treatment of metastatic hormone
relapsed prostate cancer not previously treated with chemotherapy
[ID503]. Clarification letter. Manchester: NICE; 2014. https://
www.nice.org.uk/guidance/ta387/documents/prostate-cancer-
metastatic-hormone-relapsed-not-treated-with-chemotherapy-
abiraterone-acetate-with-prednisolone-id503-evaluation-report.
Accessed 21 March 2016.
Treatment of Chemotherapy-Naı¨ve Metastatic Castration-Resistant Prostate Cancer
